REGULATORY

• 70 Institutions Picked to Treat Post-HPV Vaccine Adverse Reactions
  March 13, 2015

• PMDA Plans to Introduce Full Scale “Patient ADR Reporting System” by FY2018
  March 13, 2015

• PMDA Adopts FY2015 Project Plan Calling for Sped-Up Review
  March 12, 2015

• Japan Generic Share Little over 50% If In-House Prescriptions Included: Official
  March 11, 2015

• Mandatory CDISC-Based Submissions to Begin in October 2016
  March 11, 2015

• Panel OKs 44 More Diseases as Designated Intractable Diseases
  March 10, 2015

• MHLW to Target 75% Generic Share for Welfare Recipients
  March 10, 2015

• MHLW’s Panel on Orphan Cancer Holds First Meeting; Draft Report Expected This Summer
  March 10, 2015

• Editor’s Pick: Five Healthcare News Headlines for Feb. 23 - March 8
  March 9, 2015

• New Dosage Added to Taxol for Gastric Cancer Treatment
  March 9, 2015

• Gilead’s Sofosbuvir Likely to Get Japan Greenlight as Early as March-End
  March 6, 2015

• Govt Preparing Environment to Deliver Japanese-Originated Drugs: Amari
  March 6, 2015

• Aso Shrugs Off Question on Ibuki’s Annual NHI Price Revision Remarks
  March 6, 2015

• Ishin Submits Bill to Optimize Clinical Research
  March 5, 2015

• NCGM Opts Out of Special Mixed Care Scheme in Tokyo Economic Zone
  March 5, 2015

• Orphan Drugs for More than 50,000 Patients Can Be Developed under New Scheme
  March 3, 2015

• Pharma Might Skirt Market-Price Based Price Cuts in 2017 If Physician Fees Become Taxable
  March 3, 2015

• MHLW Won’t Order Novartis to Revise Package Inserts over Delayed ADR Reports, Urges Firms to Inspect Safety Control Regime
  March 2, 2015

• PMDA Evaluating Sitagliptin for Risk of Thrombocytopenia
  March 2, 2015

• Novartis Slapped with 15 Day Biz Suspension over Flawed ADR Reporting
  February 27, 2015

ページ

• « 先頭
• ‹ Prev
• …
• 302
• 303
• 304
• 305
• 306
• 307
• 308
• 309
• 310
• …
• Next ›
• 最終 »